Project Grant R43CA239967

The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $440,287 Project Grant to GE Medical Systems Information Technologies, Inc. (doing business as GE Healthcare Technology & Innovation Center) to establish a simplified and accessible procedure for multi-analyte simultaneous extraction of DNA, RNA, and protein from tumor touch imprints. This novel approach aims to democratize cancer biobanking for low-resource institutions,...

Micropure Genomics Inc. received a $274,199 Project Grant award from the National Science Foundation to advance methods for rapid, end-to-end sample preparation for sequencing applications. Under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), the company will develop an automated process relying on electro-hydrodynamic trapping to isolate genomic material like DNA or RNA from cells in a flow cartridge. The process aims to significantly reduce preparation time while...

This Project Grant award from the National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) supports the development of a new nucleic acid extraction technology by Vellum Biotechnology, Inc. to enable high-quality DNA sequencing from formalin-fixed, paraffin-embedded tissue (FFPET) samples. The $1,020,280 award, active from June 1, 2025 to May 31, 2027, will fund efforts to screen and select sample well components to improve the performance and manufacturability of an...

This Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) aims to develop a system to protect and concentrate large DNA molecules for genome analysis. The $394,857 project, running from August 2024 to July 2027, is being conducted by the University of Nebraska to: Develop an inverted insert to protect DNA during cell lysis, and 2) Develop a roadblock to concentrate chromosomal DNA. This innovative...

The National Cancer Institute (NCI) awarded a $400,000 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Electronic Biosciences, Inc., a small biotechnology company in San Diego, California. The goal of this 1-year project is to develop a novel nanopore-based sequencing approach that can accurately characterize repetitive DNA sequences, which are critical for understanding cancer progression but challenging to analyze using current sequencing...

This Project Grant award of $680,453 from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research to develop and validate a liquid biopsy approach using circulating tumor DNA (ctDNA) fragmentomics as prognostic and treatment resistance biomarkers for metastatic castration-resistant prostate cancer (mCRPC). The research aims to: 1) determine if baseline ctDNA fragmentomics scores are prognostic biomarkers for mCRPC, 2) detect...

The National Cancer Institute (NCI) awarded the Icahn School of Medicine at Mount Sinai a $237,023 Project Grant under the Cancer Biology Research (CFDA 93.396) program to develop a scalable and cost-effective single-cell multi-omic profiling method (SHARE-ME-SEQ). This method will jointly capture gene expression, chromatin accessibility, and DNA methylation at the single-cell level, with the goal of identifying and targeting methylation-driven pathways in acute myeloid leukemia (AML). The...

This $400,000 Project Grant award from the National Human Genome Research Institute (NHGRI) under CFDA 93.172 "Human Genome Research" will support a research program at Brigham & Women's Hospital to develop advanced computational methods for accurately identifying and genotyping structural variants within large genetic biobank datasets. The key objectives of the work are to: 1) create haplotype-informed algorithms to improve detection sensitivity and genotyping accuracy for...

This $670,147 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports research to improve the clinical sensitivity of circulating tumor DNA (ctDNA) liquid biopsies for cancer detection and monitoring. The overarching goal is to increase understanding of the molecular mediators regulating cell-free DNA (cfDNA) biogenesis and release, with the aim of developing new approaches to enhance ctDNA detection. The...

This Project Grant award, valued at $397,599, was provided by the National Human Genome Research Institute (NHGRI) under the Human Genome Research federal grant program (CFDA 93.172). The grant will fund the development of a novel epigenetic analysis method by Xgenomes Corp., a minority-owned for-profit company based in Cambridge, Massachusetts. The project aims to build out Xgenomes' single-molecule platform that can accurately detect DNA methylation patterns by measuring the repetitive binding...